Home>News> How the 8 biggest U.S. pharmas enriched their shareholders in 2019

How the 8 biggest U.S. pharmas enriched their shareholders in 2019

With tens of billions of dollars in sales pumping into their coffers each year, the world’s largest publicly traded pharmaceutical companies can be extremely profitable investments for shareholders. But impressive profits––and the welcome return on investment that comes with them––don’t always translate into more innovation or long-term value. Megapharmas spend a lot of money each year investing in short-term returns for their shareholders—including executives—instead of investing more of those profits into R&D, critics note.

Tags: